EUROAPI and Novéal sign CDMO agreement to advance cosmetic projects
09 Maggio 2023 - 7:00AM
Business Wire
- Novéal, an integral part of the L’Oréal Group, and EUROAPI
enter into a 4-year, multi-million-euro CDMO agreement
- EUROAPI to develop and industrialize the manufacturing process
of innovative cosmetic ingredients for Novéal
- This agreement is in line with EUROAPI's successful development
strategy in the CDMO since the creation of its dedicated CDMO
business development team in 2021
Regulatory News:
EUROAPI announces today the implementation of an initial 4-year
manufacturing agreement with Novéal, an integral part of the
L’Oréal Group with a focus on developing eco-responsible processes
and guaranteeing exclusive, high-performance ingredients to
sustainably meet the beauty needs of consumers around the
world.
As part of this collaboration, EUROAPI will develop and
industrialize the manufacturing process of innovative cosmetic
ingredients through its Contract Development and Manufacturing
Organization (CDMO) activity. This agreement encompasses several
projects, the first of which will take place at EUROAPI’s Frankfurt
site with a dedicated line of complex chemistry production.
“Cosmetics is a new and growing segment for EUROAPI’s CDMO
business. Signing this manufacturing agreement with Novéal
demonstrates our ability to adapt to cosmetics’ short timelines and
regulatory and quality requirements,” said Cécile Maupas, Chief
CDMO Officer of EUROAPI. “This multi-million-euro contract is a
strong recognition of EUROAPI’s broad panel of technologies and
capacities to respond to the increasing demand across different
modalities, and to guarantee full business continuity for cosmetic
ingredients.”
The CDMO activity is a strategic priority for EUROAPI. Since the
creation of its dedicated CDMO business development team in 2021,
EUROAPI has achieved substantial results and doubled the number of
customers in only one year, with 79 projects won from preclinical
phase up to commercial supply.
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to
sustainably meet customers’ and patients’ needs around the world.
We are a leading player in active pharmaceutical ingredients with
approximately 200 products in our portfolio, offering a large span
of technologies, while developing innovative molecules through our
Contract Development and Manufacturing Organization (CDMO)
activities.
Taking action for health by enabling access to essential
therapies inspires our 3,450 people every day. With strong research
and development capabilities and six manufacturing sites all
located in Europe, EUROAPI ensures API manufacturing of the highest
quality to supply customers in more than 80 countries. EUROAPI is
listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find
out more at www.euroapi.com and follow us on LinkedIn.
Forward-Looking Statements
Certain information contained in this press release is forward
looking and not historical data. These forward-looking statements
are based on opinions, projections and current assumptions
including, but not limited to, assumptions concerning the Group’s
current and future strategy, financial and non-financial future
results and the environment in which the Group operates, as well as
events, operations, future services or product development and
potential. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Forward looking
statements and information do not constitute guarantees of future
performances, and are subject to known or unknown risks,
uncertainties and other factors, a large number of which are
difficult to predict and generally outside the control of the
Group, which could cause actual results, performances or
achievements, or the results of the sector or other events, to
differ materially from those described or suggested by these
forward-looking statements. These risks and uncertainties include
those that are indicated and detailed in Chapter 3 “Risk factors”
of the Universal Registration Document approved by the French
Financial Markets Authority (Autorité des marchés financiers, AMF)
on April 14, 2023, under number R.23-009 and the Amendment to
Universal Registration Document approved by the AMF on April 25,
2023 under number R.23-015. These forward-looking statements are
given only as of the date of this press release and the Group
expressly declines any obligation or commitment to publish updates
or corrections of the forward-looking statements included in this
press release in order to reflect any change affecting the
forecasts or events, conditions or circumstances on which these
forward-looking statements are based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230508005657/en/
Media Relations Contact: Laurence Bollack Mob.: +33 (0)6
81 86 80 19 mr@euroapi.com
Investor Relations Contact: Sophie Palliez-Capian Mob.:
+33 (0)6 87 89 33 51 ir@euroapi.com
Grafico Azioni Euroapi (EU:EAPI)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Euroapi (EU:EAPI)
Storico
Da Mag 2023 a Mag 2024